The medical technology firm CytoSorbents announced on Monday that it will report its second-quarter financial results after the U.S. market closes on Thursday, July 30, 2026. The release will be accompanied by an update on recent business developments. Company management will host a conference call to discuss the results and take questions from analysts.

CytoSorbents specializes in blood purification therapies for critical care and cardiac surgery. Its flagship product, the CytoSorb® blood adsorber, is approved for commercial use in over 75 countries worldwide. It is used to control cytokine storms and remove inflammatory mediators from the blood of critically ill patients.

Market consensus estimates suggest the company's second-quarter revenue will fall between $12 million and $13 million, representing year-over-year growth of approximately 15% to 20%. Analysts are particularly focused on the company's commercial progress in the U.S. market and the accumulation of clinical evidence supporting CytoSorb® in cardiac surgery and sepsis treatment.

CytoSorbents has recently announced several business developments. These include the publication of clinical data in authoritative journals such as Critical Care Medicine on CytoSorb®'s role in reducing post-operative complications in cardiac surgery, as well as securing new reimbursement policy support in European markets. Investors are looking to the upcoming earnings report for insights into the tangible impact these developments are having on revenue.

In its first-quarter report, the company raised its full-year revenue guidance to a range of $50 million to $53 million, reflecting confidence in growing market penetration. However, CytoSorbents has not yet achieved profitability, and the market continues to monitor its cash burn rate. As of the end of the first quarter, the company held approximately $25 million in cash, which is expected to fund operations into 2027.

The earnings conference call is scheduled for 4:30 p.m. Eastern Time on July 30. Investors can listen to a live webcast via the investor relations section of the company's website.